Zydus Cadilla’s corona vaccine| Great news about Zydus Cadilla Vaccine, may get approval for emergency use this week, Zydus Cadilla’s corona vaccine Zycov D may get approval in the country this week
Requested for emergency use approval for ZyCoV-D on July 1
- Zydus Cadila requests emergency use approval for ZyCoV-D
- This shot is “needle-free,” according to the company, which is safe for children.
- Earlier, Kovishield, Covaccine, Sputnik-V have also been approved in the country.
ZyCov-D Latest News: India is soon going to get another corona vaccine on the frontline of the fight against the deadly corona epidemic, quoting sources, information has come that the corona vaccine of Zydus Cadilla can be approved in the country this week. When done, the Zydus Cadila vaccine will be the fifth corona vaccine to be used in the country.
Zydus Cadila on July 1 had requested for emergency use approval for ZyCoV-D, which if approved, will be the country’s second indigenous vaccine after Bharat Biotech’s Covaxin.
It should be noted that earlier in the country, Kovashield, Covaccine, Sputnik-V and recently Johnson & Johnson’s vaccine have also been approved. Apart from these two vaccines, Russia’s Sputnik V has also been approved.
zydus cadilla vaccine needle free
The shot is “needle-free”, safe for children according to the company, with the company planning to produce 10-12 million doses of the shot annually. India’s Drug Controller General’s approval for ZyCoV-D will make it the fifth vaccine for use in India after Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V and US-made Moderna.
Test on 28 thousand people, second phase sample also test
Zydus says it has conducted the largest clinical trial for its COVID-19 vaccine so far in over 50 centers in India. This was also the first time that any COVID-19 vaccine has been tested in the adolescent population in the 12-18 year age group in India. About a thousand subjects were enrolled in this age group and the vaccine was found to be safe and very effective. was found to be tolerable. The tolerability profile was similar to that observed in the adult population.
67% Primarily Effective
A primary efficacy of 66.6 per cent has been obtained for symptomatic RT-PCR positive cases in the interim analysis. Whereas, no common cases of COVID-19 disease were observed in the third dose vaccine arm post administration, suggesting 100% efficacy for moderate disease. There were no serious cases or deaths due to COVID-19 in the vaccine arm following the administration of the second dose of the vaccine.
#Zydus #Cadillas #corona #vaccine #Great #news #Zydus #Cadilla #Vaccine #approval #emergency #week #Zydus #Cadillas #corona #vaccine #Zycov #approval #country #week